HCV drug combo linked to side effects after liver transplant

05/16/2013 | Aidsmap

Treating hepatitis C-positive patients who underwent a liver transplant with a combination of three drugs -- pegylated interferon, ribavirin and telaprevir -- increased sustained viral response rates even for difficult cases, but adverse events were also common, according to findings presented at a liver meeting. Among the adverse events were the need for transfusions to address blood cell deficiencies. The study evaluated data from six U.S. centers.

View Full Article in:

Aidsmap

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR